You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):合作研發的新型冠狀病毒mRNA疫苗獲得墨西哥、印度尼西亞藥監部門頒發的III期臨牀試驗批件
格隆匯 08-31 19:51

格隆匯8月31日丨沃森生物(300142.SZ)公佈,公司與蘇州艾博生物科技有限公司合作研發的新型冠狀病毒mRNA 疫苗於近日分別獲得了墨西哥、印度尼西亞藥監部門頒發的III期臨牀試驗批件,標誌着新型冠狀病毒mRNA 疫苗在上述兩個國家進入III期臨牀試驗階段。

本疫苗是中國首個獲批進入臨牀試驗階段的新型冠狀病毒mRNA疫苗。近期,美國食品和藥物管理局(FDA)已批准美國輝瑞公司和德國BioNTech公司研發的新型冠狀病毒mRNA疫苗BNT162b2正式上市世界衞生組織(WHO)、歐盟以及英國、加拿大、新加坡、瑞士、阿根廷、以色列等國家藥監部門批准了該疫緊急使用授權(EUA)。同時,美國、加拿大等國家藥監部門批准了美國生物科技公司Moderna研發的新型冠狀病毒mRNA疫苗mRNA-1273的緊急使用授權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account